513 related articles for article (PubMed ID: 30181172)
1. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
[TBL] [Abstract][Full Text] [Related]
2. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
3. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
4. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
5. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
6. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
[TBL] [Abstract][Full Text] [Related]
7. Unicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
[TBL] [Abstract][Full Text] [Related]
8. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
9. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
11. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
13. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Bertinchamp R; Terriou L
Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
[TBL] [Abstract][Full Text] [Related]
17. Castleman disease.
Carbone A; Borok M; Damania B; Gloghini A; Polizzotto MN; Jayanthan RK; Fajgenbaum DC; Bower M
Nat Rev Dis Primers; 2021 Nov; 7(1):84. PubMed ID: 34824298
[TBL] [Abstract][Full Text] [Related]
18. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
19. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
20. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
